Helical Raises $10M for AI Drug Discovery Platform

London-based startup Helical has successfully closed a $10 million seed funding round, signaling a significant advancement in the application of artificial intelligence within pharmaceutical research. The investment was spearheaded by redalpine, with crucial participation from Gradient, BoxGroup, and Frst. The round also saw backing from notable angel investors, including Aidan Gomez (CEO of Cohere), Clement Delangue (CEO of Hugging Face), and football star Mario Götze, underscoring strong confidence in Helical's disruptive potential.

Founded in 2024, Helical is developing an innovative application layer platform designed to operationalize biological foundation models. This technology aims to streamline drug discovery workflows by making complex AI models accessible and actionable for pharmaceutical researchers. The company addresses a critical bottleneck in the industry: the slow pace of new drug development despite a vast number of known diseases. With over 300 billion dollars invested annually in R&D, the pharmaceutical sector faces immense pressure to increase efficiency, as more than 90% of drug candidates fail during clinical trials, and the cost per approved drug can exceed 2 billion dollars.

Helical's platform tackles the fragmentation and reproducibility issues that often hinder the translation of AI model insights into tangible research decisions. The system offers two distinct interfaces built on a unified data foundation: a 'Virtual Lab' tailored for biologists and translational scientists, and a 'Model Factory' for machine learning engineers and data scientists. This dual approach ensures that cutting-edge AI capabilities are integrated seamlessly into existing research processes, enabling faster hypothesis testing and validation.

“The models themselves don't discover drugs; the system does,” explained co-founder Rick Schneider. “Pharmaceutical teams require a robust system that transforms foundation models into executable workflows that scientists can readily employ, validate, and defend. We engineered Helical to make in-silico science reproducible at pharmaceutical scale, empowering teams to move from hypothesis to decision in days, not months.” The founding team brings a potent mix of expertise, with Schneider’s background in scaling enterprise technology at Amazon and Celonis, Allard’s data science leadership at IBM and reinforcement learning research, and Klop’s clinical experience as a cardiologist and genomics researcher.

The pharmaceutical AI market is experiencing rapid growth, driven by the need for faster R&D cycles and the increasing sophistication of biological data. Helical's approach, which bridges the gap between advanced AI models and practical laboratory application, positions it to capture a significant share of this evolving market. The company's platform is already in productive use with several top-20 pharmaceutical corporations, including a public collaboration with Pfizer focused on predictive blood-based safety biomarkers. This early traction demonstrates the platform's immediate value and scalability.

The newly acquired capital will fuel Helical's expansion, enabling the company to broaden its reach to more top-20 pharmaceutical programs and bolster its deployed science engineering team. The startup aims to deepen its engagement with existing clients across various therapeutic areas and secure new enterprise partnerships. By enhancing its evidence layer, Helical seeks to continuously improve performance across diverse disease indications, ultimately accelerating the journey from scientific concept to life-saving treatment.